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ABSTRACT:
Carbonic anhydrase IX (CAIX) is a hypoxia-inducible enzyme that is overexpressed 
by cancer cells from many tumor types, and is a component of the pH regulatory 
system invoked by these cells to combat the deleterious effects of a high rate of 
glycolytic metabolism. CAIX functions to help produce and maintain an intracellular 
pH (pHi) favorable for tumor cell growth and survival, while at the same time 
participating in the generation of an increasingly acidic extracellular space, 
facilitating tumor cell invasiveness. Pharmacologic interference of CAIX catalytic 
activity using monoclonal antibodies or CAIX-specific small molecule inhibitors, 
consequently disrupting pH regulation by cancer cells, has been shown recently to 
impair primary tumor growth and metastasis. Many of these agents are in preclinical 
or clinical development and constitute a novel, targeted strategy for cancer therapy.
INTRODUCTION
Hypoxia is a salient feature of many types 
of solid cancers and arises as the result of spatial 
disorganization and flow-based disruption of an abnormal 
microvasculature initiated by the growing tumor [1]. The 
impact of tumor hypoxia is multifaceted, with effects 
on several aspects of tumor biology, including genetic 
instability,  angiogenesis,  invasiveness,  survival  and 
metabolism [1, 2]. Reduced oxygen availability leads to 
the activation of a core cellular response to hypoxia, the 
master regulators of which are the transcription factors 
hypoxia-inducible factor 1 and 2 (HIF-1/2) [2]. Initiation 
of this core hypoxia-induced signaling cascade results 
in the activation of a vast array of genes, and from these 
arise signaling outputs that regulate a variety of processes 
aimed at adaptation of tumor cells to conditions of low 
oxygen [2]. Amongst the stressors imposed by hypoxia, 
the reduced supply of oxygen limits the capacity for 
oxidative phosphorylation as a means of producing energy 
[3, 4]. Hypoxic, HIF-1α-activated tumor cells respond to 
this microenvironmental stress by reprogramming their 
metabolism to engage the glycoytic pathway, a process 
that is far less efficient, but does not rely on the presence 
of oxygen. This “glycolytic switch” is often permanent 
and  persists  after  reoxygenation,  in  part  because  the 
byproducts of glycolysis can be used for anabolic reactions 
that provide a selective advantage to highly proliferative 
tumor cells [3, 4]. The high rate of glycolysis maintained 
by cancer cells is the basis for the Warburg effect [3, 5].
The switch to glycolysis by highly metabolically 
active tumor cells results in increased production and 
export of acidic metabolites, such as lactic and carbonic 
acids, to the extracellular space and leads to a decline in 
extracellular pH (pHe) [6], creating a toxic intratumoral 
microenvironment and providing a selective advantage 
for tumor cells that can survive these harsh conditions. 
One  consequence  of  extracellular  acidification  is  the 
disruption of the intracellular pH (pHi), a decrease in 
which rapidly affects basic cellular functions, including 
membrane integrity, metabolism and energy production, 
and proliferation [4, 6]. Thus, cells must regulate pHi as 
the extracellular pH declines, a process particularly critical 
for tumor cells that prefer a pHi that is somewhat more Oncotarget 2012; 3:  84 - 97 85 www.impactjournals.com/oncotarget
alkyline compared to that which is optimal for normal 
cells [4, 7]. The combination of an increasingly acidic 
intratumoral microenvironment and a requirement to 
regulate pHi results in the death of non-tumor cells and 
accelerates degradation of the extracellular matrix, thereby 
promoting the invasion and proliferation of acid-resistant 
cancer cells. As such, metabolic alterations induced by 
hypoxia can promote activities associated with aggressive 
tumor  cell  behavior,  including  survival,  invasion  and 
metastasis [8].
The  maintenance  of  pH  homeostasis  by  tumor 
cells relies on a set of complex molecular mechanisms 
involving a variety of proteins and buffer systems with 
the central aim of maintaining a moderately alkaline 
pHi  while  generating  a  markedly  acidic  extracellular 
environment [4, 6]. One set of proteins important to this 
pH regulatory system is the family of carbonic anhydrases 
(CAs) [6, 9]. CAs are a family of 16 distinct, but related 
metalloenzymes whose major enzymatic function is to 
catalyze the reversible hydration of carbon dioxide (CO2) 
to bicarbonate (HCO3
- and protons (H+) (CO2 + H2O ↔ 
HCO3
- + H+) [9]. As a group, CAs are important regulators 
of a variety of biological processes, including respiration, 
acid-base regulation, bone resorption and calcification, and 
biosynthetic processes [9]. In the context of tumors, two 
particular isoforms, CAIX and CAXII, are associated with 
cancer progression, metastasis, and impaired therapeutic 
response [4].
CAIX BIOCHEMICAL STRUCTURE
CAIX  was  initially  identified  as  a  membrane-
bound protein on the surface of the HeLa human cervical 
carcinoma cell line and was named the “MN protein” [10, 
11]. However, subsequent analysis of its cDNA sequence 
revealed  the  presence  of  a  257  aa  long  extracellular 
carbonic  anhydrase  (CA)  domain,  resulting  in  the 
acquisition of its current namesake [12, 13]. The recent 
solution of the structure of the catalytic domain of CAIX 
[14] has provided structural confirmation of its observed 
catalytic activity and has aided in more rational drug 
design [15-17]. In contrast to other CA isoforms, CAIX 
is dimeric [17], is among the most active CA for the CO2 
hydration reaction [16] and contains a proteoglycan (PG)-
like domain immediately adjacent to the catalytic domain, 
the presence of which may allow the enzyme to function 
most efficiently at more acidic pH values [17, 18]. A single 
pass transmembrane domain separates the extracellular 
portion of CAIX from a short, intracellular tail that is 
involved in regulating its enzymatic activity [19].
REGULATION OF CAIX EXPRESSION
The transcriptional regulation of CAIX has been 
reviewed in detail recently [20] and the discussion here 
is limited its regulation as it pertains to cancer biology. 
Expression of CAIX by tumor cells is generally very 
low in normoxia, but levels are strongly induced during 
hypoxia [21-23]. The CAIX promoter contains a hypoxia 
responsive element (HRE) that is located immediately 
upstream  of  the  transcription  start  site  and  that  binds 
HIF-1α [21]. Indeed, HIF-1α is the exclusive regulator 
of CAIX activity, in contrast to many hypoxia-induced 
genes, and CAIX is often the most strongly upregulated 
gene in response to hypoxia in human cancer cells [9, 20]. 
Additional transcription factor binding sites present in 
the CAIX promoter appear to coordinate with the HRE to 
promote or amplify the HIF-1 response [20, 24]. 
Importantly, the signaling pathways, soluble factors, 
and microenvironmental conditions that regulate CAIX 
transcription converge on the HIF-1 pathway and CAIX 
expression is coupled directly both to increased protein 
stabilization and transcriptional activity of HIF-1 [20]. 
However,  cancer  cells  grown  to  high  density  in  vitro 
develop pericellular hypoxia and can upregulate the 
expression of CAIX as a consequence increased HIF-1 
transcriptional activity, but in the absence of detectable 
stabilization  of  HIF-1,  effectively  “uncoupling”  these 
two arms of HIF-1 regulation [20, 25, 26]. Culturing 
cancer cells at high density also induces signaling 
pathways,  including  the  phosphatidylinositol  3-kinase 
(PI3K) pathway. Under these conditions, PI3K inhibitors 
suppress CAIX expression, revealing that CAIX is driven 
by increased transcriptional activity of HIF-1α resulting 
from mild hypoxia and PI3K activation [25, 27].
While hypoxia is the key driver of CAIX expression 
in cancer cells, there are also data suggesting that 
microenvironmental conditions, tumor suppressors and 
oncogenic signaling pathways may play a role in specific 
circumstances. In studies using glioblastoma cells grown 
in  normoxia,  acidification  of  the  growth  media  was 
associated with increased CAIX promoter activity and 
upregulated  CAIX  expression,  and  was  attributed  to 
HIF-1 stabilization and activation of extracellular signal-
regulated kinase (ERK) [28]. However, modulation of pHe 
had no effect on CAIX expression in normoxic HeLa cells 
[29], indicating that pH-driven upregulation of CAIX may 
be cell-type specific. The role of glucose deprivation has 
also been investigated, but results remain inconclusive, 
with  some  studies  reporting  heightened  expression  of 
hypoxia-induced CAIX in response to restricted glucose 
[29], while others have reported reduced CAIX expression 
in these conditions [30]. With regard to tumor suppressors, 
the best characterized example is the role of VHL in 
CAIX upregulation wherein mutation of VHL results in 
constitutive stabilization of HIF-1 in normoxia and drives 
hypoxia-independent expression of HIF-1 regulated genes, 
including CAIX [31]. Indeed, this mechanism results in 
the uniformly high CAIX expression reported in clear cell 
renal cell carcinoma [31]. P53 has also been shown to 
modulate CAIX expression, but again the primary target is 
HIF-1 [32]. Similarly, modulation of CAIX activity by the Oncotarget 2012; 3:  84 - 97 86 www.impactjournals.com/oncotarget
PI3K pathway and the ERK pathway have been reported, 
but the effects are cell-specific and the modulation of 
CAIX is likely secondary to the modulation of relevant 
transcription factors (HIF-1, SP1/SP3, AP1) [20, 25, 27].
THE ROLE OF CAIX EXPRESSION IN 
NORMAL TISSUE
CAIX expression in normal tissue
CAIX is an especially attractive target for cancer 
therapy, in part because it is overexpressed in a wide 
variety  of  solid  tumors,  but  is  expressed  in  a  limited 
way in normal tissues. Early studies established that the 
differential distribution in cancerous versus normal tissue 
is not the result of mutations [33]. In human tissue, strong 
expression of CAIX is generally limited to the basolateral 
surface of proliferating crypt enterocytes of the duodenum, 
jejunem and ileal mucosa in the human [34]. However, 
diffuse, weak CA IX expression has also been reported in 
the epithelia of human male efferent ducts [35], as well as 
in occasional foci in the pancreatic acini [36]. Analyses 
based on cDNA demonstrated the presence of CA IX 
in gall bladder epithelia [33], but protein has not been 
detected.
In  mice,  CAIX  expression  is  evident  by  days 
E11.5-E12.5 [37, 38] and is expressed to significant levels 
in the brain, lung, liver and pancreas, while weak signals 
are evident in the kidney and stomach [38]. Expression 
in the normal adult is restricted to a few tissues, with the 
gastric mucosa exhibiting the highest levels of protein 
[37].  Post  transcriptional  control  of  CAIX  may  be 
evident in some tissues as relatively strong signals were 
observed for CAIX mRNA in the kidney and skeletal 
muscle of Balb/c mice, but these tissues showed little or 
no expression of the protein [37]. Indeed, normal human 
kidney and muscle are essentially null for CAIX mRNA 
and protein [39]. Mice also show expression of CAIX in 
pancreatic acini in a diffusely distributed pattern [37].
Phenotypes in CAIX knock-out animals
As  would  be  predicted  from  the  observations  of 
restricted expression of CAIX in normal adult tissues, 
genetic disruption of CAIX expression in mice results in 
mild phenotypes. Global knockout of CAIX in mice by 
targeted gene disruption resulted in homozygous animals 
developing gastric hyperplasia of the glandular epithelium, 
including  numerous  cysts  [40].  The  hyperplasia  was 
prominent within  4 weeks  after birth  and loss of  CA 
IX  expression  led  to  increased  numbers  of  pit  cells 
and depletion of pepsinogen-secreting chief cells [40]. 
However, mice developed normally and showed normal 
gastric pH, acid secretion and serum gastrin levels [40]. 
No effect on the hyperplasia and no dysplasia were noted 
when  knockout  animals  were  challenged  with  a  high 
salt diet [41], although gastric submucosal inflammation 
was noted in one mouse strain [41]. Importantly, CAIX 
deficiency did not promote tumorgenicity [41], although 
aged CAIX null mice may suffer degenerative disease in 
the brain. At 8 to 10 months of age, vacuolar degenerative 
morphological changes were noted in knockout animals 
[42]. Interestingly, CAIX expression is upregulated about 
2 –fold in mice null for CAII [43], suggesting the presence 
of functional redundancy amongst the CA isozymes.
CAIX EXPRESSION IN TUMOR TISSUE
The  discussion  above  reinforces  the  fact  that 
CAIX expression in the normal adult is highly restricted 
and that interference with its function in normal tissue 
likely has few, if any, significant consequences, except 
perhaps in chronic, age-related situations. On the other 
hand, CAIX is overexpressed in many solid tumors and 
there  is  now  a  well-established  relationship  between 
the expression of CAIX and patient prognosis. CAIX 
expression, as detected by immunohistochemical staining 
of tissue sections, is upregulated and associated with poor 
prognosis in cancers of the lung [44-46], colon [47, 48], 
breast [49-51], cervix [52-55], bladder [56], ovaries [57], 
brain [58], head and neck [59-61], and oral cavity [62, 63]. 
Furthermore, recent studies have examined the expression 
of CAIX in cohorts of hundreds to thousands of patients 
using tissue microarray (TMA) strategies (Table 1). Using 
this high throughput platform, CAIX has been validated 
as a biomarker of poor prognosis in breast [23, 64], lung 
[46], ovarian [57] and bladder cancer [65], as well as in 
astrocytomas [66].
While  the  vast  majority  of  studies  support 
a  correlation  between  CAIX  overexpression  and 
patient  prognosis,  a  few  studies  have  failed  to  find  a 
relationship. For example, in a TMA study of 99 patients 
that  encompassed  pre  and  post  (chemo)radiotherapy 
biopsies,  CAIX  was  detected  in  over  85%  of  pre-
treatment specimens [67]. However, the study failed to 
find a relationship with prognosis, probably because of 
insufficient numbers of patients [67]. On the other hand, 
in a series of 166 patients with rectal cancer where full 
tissue sections were used, 44% were positive for CAIX 
expression  and  two  thirds  of  these  patients  showed 
moderate to strong staining [48]. High CAIX expression 
was indicative of shorter disease-free and disease specific 
survival,  and  was  demonstrated  to  be  an  independent 
poor prognostic biomarker [48]. Similarly, most clinical 
studies have demonstrated that a high level of CAIX is a 
biomarker of poor prognosis both in local advanced [52-
55] and in early stage [68, 69] cervical cancer, but some 
studies have failed to find a correlation [70]. 
In  addition  to  overall  prognostic  information, 
interrogation of TMAs has revealed associations between Oncotarget 2012; 3:  84 - 97 87 www.impactjournals.com/oncotarget
CAIX overexpression and specific tumor categories. For 
example, CAIX is particularly highly expressed in basal-
like or triple negative breast cancers, a tumor subgroup 
with poor prognosis and known resistance to therapy [23, 
51]. Tumor type dependence has also been reported in 
lung cancer, with a higher percentage of CAIX positive 
tumors  amongst  the  squamous  cell  phenotype  [46]. 
Clinical studies have also revealed a correlation between 
CAIX expression and metastatic disease. Most recently, 
interrogation of over 3600 human breast cancers provided 
definitive evidence of CAIX as an independent biomarker 
of  poor  prognosis  for  distant  metastases  [23].  CAIX 
expression was interrogated in a TMA series of 930 breast 
cancers categorized according to patient survival and 
overexpression was correlated with death and metastatic 
disease [71]. Several studies have now demonstrated that 
CAIX levels are associated with metastasis-free survival 
in multivariate analyses [52-54, 69], and high levels of 
CAIX expression are associated with greater lymph node 
metastases [54, 55].
There is now increasing focus on the use of soluble, 
plasma  CAIX  for  clinical  detection  and  prognostic 
evaluation. Initial studies involving relatively small sample 
sizes showed that soluble, serum CAIX was upregulated 
in patients with solid tumors [72, 73] and could be used 
to detect clinically relevant disease, although prognostic 
impact was not realized. However, recent studies have 
shown an association between soluble CAIX and patient 
prognosis. Preoperative serum CAIX concentrations in 
vulvar  cancer  correlated  with  intratumoral  expression 
and increased serum CAIX levels were associated with 
poor prognosis [74]. Serum levels of CAIX in metastatic 
breast cancer were also correlated with poor prognosis, as 
well as with the incidence of circulating tumor cells [75]. 
Similarly, in NSCLC, high plasma levels of CAIX were 
associated with significantly shorter overall survival [46].
BIOLOGICAL FUNCTIONS OF CAIX IN 
CANCER CELLS
CAIX and control of tumor pH
The role of CAIX in the control of pH dynamics 
in  solid  tumors  is  now  well-recognized  [6,  76]. 
The  maintenance  of  pH  homeostasis  by  tumor  cells 
encompasses several complex molecular mechanisms 
involving a variety of proteins and buffer systems with the 
central aim of maintaining a moderately alkaline pHi while 
generating a markedly acidic extracellular environment 
[6]  (Figure  1).  Indeed,  tumor  cells  generally  favor  a 
more alkaline pHi than their normal counterparts [4]. A 
change in the pHi/pHe ratio of 0.1-0.2 pH units can have 
disasterous consequences for critical biological processes 
including ATP synthesis, proliferation, migration, survival 
and metastasis [6, 8]. The primary enzymatic function of 
CAIX is to catalyze the reversible hydration of carbon 
dioxide to bicarbonate and protons (CO2 + H2O ↔ HCO3
- 
+ H+). The location of the active site of CAIX on the 
extracellular surface of the plasma membrane positions it 
well for the enzyme to contribute to acidification of the 
tumor microenvironment in hypoxia. In fact, CAIX has 
been said to act as a “catalytic converter” for the excretion 
of acid from cells [77]. Bicarbonate is shuttled into the 
cytoplasm to buffer pHi, while the proton remains in the 
extracellular space. Thus, CAIX has a dual role in the 
growth  of  hypoxic,  CO2  excreting  tumors  (Figure  1). 
First, it helps to produce and maintain an alkyline pHi 
favorable for tumor growth. Second, it participates in the 
generation of an increasingly acidic extracellular space, 
facilitating tumor cell invasiveness [6, 76, 77]. Inhibition 
of CAIX interferes with removal of acid and results in a 
decrease in pHi, negatively influencing cell survival [76, 
77] (Figure 1). Furthermore, low pHe is associated with 
tumorigenic transformation, chromosomal rearrangements, 
extracellular matrix breakdown, migration and invasion, 
Cancer Type 
[citation]
# of Samples
Total CAIX 
+ve (%)
Prognostic Indicator
Univariate Analysis Multivariate Analysis
DSS OS MFS DSS OS MFS
Breast [23] 3630 16 Yes NR Yes Yes Yes Yes
Breast [64] 144 26 NR Yes NR NR Yes NR
NSCLC [46] 555 24 Yes Yes NR Yes NS NR
Ovarian [57] 205 26 NR Yes NR NR Yes NR
Bladder [65] 340 71 NR Yes NR NR Yes NR
Astrocytoma [66] 362 78 NR Yes NR NR Yes NR
DSS, disease specific survival; OS, overall survival; MFS, metastasis free survival; NR, not reported; NS, not significant.
Table 1: Tissue microarray studies evaluating CAIX as a poor prognostic biomarker in human cancerOncotarget 2012; 3:  84 - 97 88 www.impactjournals.com/oncotarget
protease activation and growth factor production [6, 76]. 
Inhibition of CAIX would also attenuate these processes, 
thereby reducing tumor growth and invasion (Figure 1).
Regulation of CAIX activity
Recent data have suggested that the regions flanking 
the catalytic domain, in particular the PG-like domain 
and the intracellular tail, are critical for modulating the 
catalytic activity of CAIX. The PG-like domain allows 
CAIX to remain highly catalytically active at low pH 
values that would kill most enzymes [17]. Mutagenesis 
of a cluster of basic amino acids in the intracellular tail 
affected the function of the extracellular catalytic domain, 
suggesting that the cytoplasmic tail plays a role in inside-
out signaling [78, 79]. In addition, the intracellular tail 
contains three potential phosphorylation sites, 443T,  448S 
and 449Y. Data suggest that 449Y plays a role in EGF-R-
induced  signaling  to Akt  [80],  while  cAMP-mediated 
activation  of  PKA  in  hypoxia  leads  to  PKA-induced 
phosphorylation on 443T of CAIX, resulting in increased 
activity [19]. Interestingly, full activation of CAIX also 
appears to require dephosphorylation of 448S [19].
CAIX in cell adhesion, migration and proliferation
In addition to its role in the regulation of tumoral 
pH and tumor cell survival, there is evidence that 
CAIX  contributes  to  cell  processes  such  as  adhesion 
and  migration,  both  of  which  are  vital  for  metastatic 
progression  in  human  cancer.  In  CAIX-null  MDCK 
cells  constitutively  expressing  human  CAIX,  the 
Figure 1: Pharmacologic inhibition of CAIX activity inhibits cancer cell survival and invasion. Hypoxia induces a HIF-
1-mediated signaling cascade that results nuclear translocation of HIF-1α and activation of hypoxia-regulated genes, including GLUT1, 
MCT1/4 and CAIX. Cells reprogram their metabolism to engage the glycoytic pathway, a “glycolytic switch” that results in increased 
production and export of lactate, leading to a decline in pHe. One consequence of extracellular acidification is the disruption of the 
intracellular pH (pHi), a decrease in which rapidly affects basic cellular functions. The overexpression of CAIX in hypoxia catalyzes the 
hydrolysis of CO2 to HCO3
- and H+ in the extracellular microenvironment. The HCO3
- is actively transported into the cancer cell, thereby 
regulating pHi and maintaining cell survival. The H+ participate in the generation of an increasingly acidic extracellular space, promoting 
tumor cell invasiveness. Inhibition of CAIX catalytic activity using monoclonal antibodies or specific small molecule inhibitors prevent the 
production of these enzymatic metabolites, leading to decreased survival and reduced invasive capacity.
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protein localized to cell-cell junctions and overlapped 
with  staining  for  E-cadherin  [81].  Reoxygenation  of 
hypoxia-cultured cells resulted in delocalization of CA 
IX and E-cadherin from the membrane to the cytoplasm, 
followed by relocalization to the membrane upon return 
to hypoxia [81]. CAIX-expressing MDCK cells showed 
lower  cell  adhesion  and  CA  IX  immunoprecipitated 
with  β-catenin  in  these  cells,  suggesting  that  CAIX 
may  modulate  E-cadherin-mediated  cell  adhesion  by 
competing  with  E-cadherin  for  binding  to  β-catenin 
[81].  Gene  expression  analysis  of  cervical  carcinoma 
cells overexpressing exogenous human CAIX revealed 
differential regulation of genes involved in cell growth, 
cell adhesion and cytoskeletal organization [82]. These 
cells showed weakened cell-cell adhesion and increased 
cell  motility.  Moreover,  constitutive  CAIX  expression 
induced inactivation of Rho and led to EMT in these cells 
[82]. The expression of CAIX may also be involved in 
cell proliferation. Several studies have also reported a 
reduction  in  proliferation  when  CAIX  is  inhibited,  at 
least in cells exogeneously overexpressing CAIX [83-85]. 
Together, these studies suggest that inhibition of CAIX in 
hypoxic tumors may have anti-tumor effects that extend 
beyond control of intratumoral pH.
PHARMACOLOGIC INHIBITION OF 
CAIX AS A MEANS OF THERAPEUTIC 
INTERVENTION IN CANCER
CAIX is an attractive target for anticancer therapy 
for several reasons. It is selectively expressed by tumor 
cells and shows highly restricted expression in normal 
tissue. It provides functions critical for tumor growth 
and metastasis, including pH regulation, survival and 
adhesion/migration. It is positioned on the extracellular 
surface of cell membranes, allowing efficient targeting 
by antibodies or small molecule inhibitors. Furthermore, 
genetic silencing of CAIX in preclinical tumor models in 
vivo has demonstrated the requirement of CAIX for the 
growth of hypoxic tumors and their metastasis. Genetic 
depletion of CAIX, together with CAXII, in LS147Tr 
colorectal cancer xenografts resulted in an 85% reduction 
in tumor growth [86]. Silencing of CAIX expression in 
4T1  mouse  metastatic  breast  cancer  cells  resulted  in 
regression of orthotopic mammary tumors and inhibition 
of spontaneous lung metastasis formation [23]. Stable 
depletion of CAIX in MDA-MB-231 human breast cancer 
xenografts also resulted in attenuation of primary tumor 
growth [23]. These studies provide proof of principle data 
showing that inhibition of CAIX is of potential therapeutic 
benefit. Two major tools that are being investigated for 
their efficacy as CAIX-specific therapeutic modalities in 
cancer treatment are monoclonal antibodies and small 
molecule inhibitors.
Monoclonal antibodies
Immunotherapy  using  CAIX-specific  monoclonal 
antibodies (mAbs) may derive its therapeutic efficacy 
through  a  variety  of  mechanisms.  Direct  binding  of 
the  mAb  to  CAIX  can  elicit  an  anti-tumor  response 
due  to  antibody-mediated  cell  cytotoxicity  (ADCC). 
Alternatively,  receptor-mediated  internalization  allows 
for targeted delivery of various therapeutic  payloads, 
including  cytotoxins  and  radionuclides.  Furthermore, 
development  of  mAbs  targeting  the  CAIX  active  site 
provides  potential  for  selective  blocking  of  CAIX 
function.
Historically, two mAbs, M75 [10] and G250 [87], 
have dominated as CAIX-specific immunological tools 
for clinical detection and/or therapy. M75 is a highly-
specific antibody targeting the PG-like domain of CAIX 
and it is used widely for immunohistochemical detection 
of  CAIX  in  human  tumor  tissue  [79]. A  radiolabeled 
derivative  has  been  developed  for  imaging  CAIX  in 
hypoxic tumors preclinically [88, 89], but M75 has not 
been developed for application as an immunotherapy. In 
contrast, a chimeric version of G250, cG250, has been 
developed and extensively characterized as an anticancer 
immunotherapy [90]. Early studies showed that cG250 
could  elicit  antibody-dependent  cellular  cytotoxicity 
(ADCC)  [91],  an  established  mechanism  by  which 
therapeutic mAbs mediate tumor cell destruction. Phase 
I and II trials demonstrated that this Ab was safe, well-
tolerated and able to positively impact disease burden, 
alone and together with interferon (IFN)-α treatment [92, 
93]. cG250 is currently marketed by WILEX AG under 
the trade name RENCAREX® and phase III trials have 
now been initiated using cG250 as an adjuvant therapy 
aimed at reducing recurrence in surgically-treated renal 
cell carcinoma (RCC) patients who have a high risk of 
relapse and in combination with interleukin 2 (IL-2) or 
IFN-α for metastatic RCC [4, 79, 92].
While  M75  and  cG250  are  directed  at  the  PG-
like domain of CAIX, recent studies have focused on 
developing  antibodies  targeted  against  its  catalytic 
domain.  These  antibodies  have  the  advantage  of 
specifically disrupting the catalytic activity of the enzyme, 
thus targeting its tumorigenic functions, including pH 
regulation.  High  throughput  screening  technologies, 
especially the use of phage display libraries [94-96], have 
been employed to efficiently identify CAIX antibodies. 
Epitopes of some of the fragments have mapped to the 
catalytic site, and these have been shown to inhibit CAIX 
activity in vitro [94, 96]. Inhibition of CAIX in spheroid 
cell cultures has also been demonstrated, suggesting that 
these mAbs could be used to inhibit CAIX therapeutically 
[94]. However, in vivo experiments demonstrating efficacy 
as anti-tumor agents have not been performed. Two mAbs 
generated  by  phage  display  and  with  high  affinity  to 
CAIX have been shown to bind CAIX in tumors in vivo Oncotarget 2012; 3:  84 - 97 90 www.impactjournals.com/oncotarget
[95], but again, evaluation of anti-tumor efficacy was not 
performed. On the other hand, a mAb directed against the 
CAIX catalytic domain and generated using hybridoma 
technology has been developed and tested in vivo [79]. 
The mAb showed efficient binding, internalization and 
persistence in cultured cells. In vivo evaluation in HT-
29  colorectal  xenografts  demonstrated  that  treatment 
immediately after cell inoculation effectively limited 
tumor growth, but the effect was very modest when tumors 
were allowed to establish prior to treatment [79]. 
While  selective  inhibition  of  CAIX  catalytic 
activity by mAbs exploits the property of mAbs to not 
spontaneously cross the plasma membrane, the utility 
of  mAbs  in  cancer  therapy  is  often  driven  by  their 
ability to undergo receptor-mediated internalization. Ab 
internalization is required for delivery of therapeutic 
payloads, including radionuclides and cytotoxic drugs, and 
CAIX Abs have been developed to exploit this property. 
For example, a portion of the cG250 Ab is internalized, 
and metallic radionuclides, including 177Lu and 90Y, have 
been introduced into cellular lysosomes using cG250 in 
mice, producing a therapeutic growth delay in xenograft 
tumors [97]. A phase I/II trial in metastatic RCC patients is 
currently ongoing [98]. In a very recent study a CAIX mAb 
identified from a phage display library was conjugated to 
monomethyl auristatin E (MMAE) and the efficacy of 
this Ab-drug conjugate (BAY79-4620) was evaluated in 
several preclinical human xenograft tumor models [99]. 
Drug delivery to target cells involved internalization of 
the mAb and anti-tumor efficacy correlated with CAIX 
expression, with tumors showing the most robust levels of 
CAIX expression also having the best therapeutic response 
[99].
CAIX-specific small molecule inhibitors
Several  broad  classes  of  small  molecules  are 
known to effectively inhibit CAs [4, 9], and compounds 
based  on  sulfonamide/sulfamates  and  coumarins  have 
demonstrated particular promise as potential anti cancer 
agents.  Interestingly,  these  two  inhibitor  classes  are 
mechanistically distinct in their inhibition of CAs. The 
sulfonamides inhibit CAIX by coordinating to the zinc ion 
within the active site, while molecules based on coumarin/
thiocoumarin  act  as  suicide  inhibitors,  undergoing 
hydrolysis  to  2-hydroxycinnamic  acids  and  binding 
irreversibly at the entrance to the active site cavity [100, 
101]. 
Evaluation of CAIX inhibitors in cell culture
The high degree of homology amongst the catalytic 
sites  of  the  various  mammalian  CAs  has  presented  a 
challenge to the design and development of isozyme-
specific  agents.  The  development  of  compounds  that 
selectively inhibit tumor associated, extracellular CAs 
without “off-target” inhibition of intracellular CAs such 
as CAII is critical for their use as cancer therapeutics 
[4, 9]. Several strategies have evolved to “dial in” the 
selectivity of small molecule inhibitors of CAIX, such 
as the addition of charges species, bulky entities such 
as FITC or albumin or hydrophilic sugar moieties, all of 
which limit transport across the plasma membrane [4, 9]. 
Tumor Model [citation] Inhibitor Effect
LS174T human colon carcinoma [109] fluoro-acetazolamide bound to xenograft tissue; no significant effect 
on tumor growth
SK-RC-52 human renal cell carcinoma [109] albumin-acetazolamide significant reduction in tumor growth
HT-29 human renal cell carcinoma [110] bis sulfonamide tumor-specific accumulation; effect on tumor 
growth not measured
HT-29 human renal cell carcinoma [111] fluorescent sulfonamide tumor-specific accumulation; effect on tumor 
growth not measured
4T1 metastatic mouse breast cancer [23] fluorescent sulfonamide significant inhibition of tumor growth
4T1 metastatic mouse breast cancer [23, 102] ureido sulfonamides inhibition of experimental lung metastases
4T1 metastatic mouse breast cancer [23, 103] glycosyl coumarins inhibition of experimental lung metastases; 
inhibition of primary tumor growth
MDA-MB-231 LM2-4 lung metastatic breast 
cancer [23]
ureido sulfonamides inhibition of primary tumor growth
HT-29 human renal cell carcinoma [84] indanesulfonamide inhibition of primary tumor growth; synergy 
with radiotherapy
Table 2: Targeting of CAIX by small molecules in preclinical models of human cancerOncotarget 2012; 3:  84 - 97 91 www.impactjournals.com/oncotarget
Other approaches include the use of distinct chemotypes of 
sulfonamides [102] or coumarins [103] that are inherently 
selective for extracellular CAs such as CAIX. Many of 
these  compounds  have  been  evaluated  as  both  potent 
and selective for CAIX based on in vitro assays using 
recombinant CAs. In some studies, efficient attenuation of 
cell growth by a series of chemically defined CA inhibitors 
has been demonstrated using panels of cultured tumor 
cell lines representing a variety of types of cancers [104, 
105]. While these studies have identified CA inhibitors as 
potential anti-cancer therapeutics, the experiments were 
performed in normoxia without analysis of CAIX status, 
thus evaluation of the specific role of CAIX on tumor cell 
viability was not possible. Indeed, these studies suggest 
that some of these CA inhibitors may work effectively 
as cytotoxic agents in cancer therapy [104, 105]. Ideally, 
inhibitors that specifically target CAIX-overexpressing 
cancer cells while exhibiting no effects on normal, CAIX-
negative cells would be desired.
A  growing  number  of  selective  CAIX  inhibitors 
have  been  evaluated  in  cell  culture  models  and  have 
provided  evidence  both  of  their  CAIX-specific  nature 
and their potential as anti-tumor agents. To date, the best 
characterized CAIX-selective small molecule inhibitor 
is  a  FITC-labeled  fluorescent  sulfonamide  [9].  This 
compound has a high affinity for extracellular CAs. Cell 
culture studies using both MDCK cells that overexpress 
CAIX  and  human  tumor  cell  lines  that  constitutively 
express CAIX or induce the enzyme in hypoxia have 
demonstrated  that  this  inhibitor  binds  only  to  active 
CAIX in hypoxia [23, 106] and inhibits CAIX-mediated 
acidification of the extracellular environment [23, 106, 
107].  Interestingly,  similar  data  was  reported  recently 
for a fluorescently labeled sulfamate [84]. The influence 
of CAIX inhibitors on cancer cell viability has also been 
investigated. Human renal carcinoma cell lines with or 
without constitutive expression of CAIX, together with 
cell density dependent upregulation of CAIX in HeLa 
cells, were used as models to test the functional impact of 
two aromatic sulfonamides, TR1 and GA15 [83]. Results 
showed that these inhibitors preferentially reduced pHi 
and proliferation, and induced apoptosis and ceramide 
production  in  CAIX-positive  cells,  but  not  in  CAIX-
negative cells [83]. Treatment with an indanesulfonamide 
CAIX inhibitor in HT-29 human colon carcinoma cells 
resulted in reduced proliferation and increased apoptosis, 
but did not affect intrinsic radiosensitivity in this cell line 
[84]. Such studies demonstrate that sulfonamide inhibitors 
can be engineered to bind selectively to CAIX and inhibit 
its biological functions in cell culture. Interestingly, some 
of these experiments were carried out in normoxia [83], 
suggesting  that  certain  CAIX  inhibitors  may  function 
regardless  of  hypoxia-induced  activation.  Thus,  these 
inhibitors can negatively impact cancer cell viability in a 
CAIX-dependent manner.
Evaluation of selective CAIX inhibitors in 
preclinical models
Despite  great  scientific  interest  in  CAIX  as  a 
biomarker,  imaging  target  and  therapeutic  target  for 
hypoxic tumors, preclinical evaluation of targeted agents 
remains in its infancy. The paucity of appropriate, CAIX-
positive preclinical models and the complexities involved 
in synthesizing small molecule inhibitors that are highly 
selective for the CAIX isozyme remain as challenges 
in  the  field  [4,  23,  108].  Recently,  however,  progress 
has been made in developing small molecule inhibitors 
with reasonable selectivity for extracellular CAIX that 
demonstrate efficacy in vivo (Table 2). 
Initial attempts to target CAIX therapeutically in 
vivo used inhibitors based on acetazolamide, onto which 
albumin binding moieties or charged flurophores were 
attached, thereby restricting the binding of acetazolamide 
to extracellular CAs [109]. The fluorophore-conjugated 
inhibitor  bound  to  LS174T  human  colon  carcinoma 
xenograft tissue in a pattern similar to that seen with 
antibodies against CAIX, but a decrease in tumor growth 
was not observed in this model [109]. However, treatment 
of  SK-RC-52  human  renal  cell  carcinoma  xenografts 
constitutively expressing CAIX with the albumin-binding 
variant did produce a significant decrease in tumor growth 
[109].  The  inhibitor  was  also  effective  when  used  in 
combination  with  sunitinib,  although  the  combination 
treatment did not significantly outperform sunitinib alone 
[109], likely because of the high efficacy of sunitinib in 
this tumor model. More recently, one of several potent bis-
sulfonamide CAIX inhibitors identified in a screen of 1 
million compounds in a DNA-encoded chemical library 
was found to exhibit strong tumor-specific accumulation 
in these tumor models [110]. Tumor-specific, oxygen-
dependent  localization  of  the  established  fluorescent 
sulfonamide inhibitor of CAIX in HT-29 colon carcinoma 
xenografts has also been reported [111]. While tumor 
growth inhibition per se was not measured in these studies, 
the results indicate the ability of highly selective CAIX 
inhibitors to bind specifically to their target in vivo.
Recent  studies  have  now  demonstrated  that 
CAIX-selective sulfonamide inhibitors can directly and 
specifically inhibit the growth of hypoxic, CAIX-positive 
tumors in preclinical animal models. Treatment of hypoxic, 
metastatic  4T1  mouse  breast  tumors  in  an  orthotopic 
setting with an established fluorescent sulfonamide CAIX 
inhibitor resulted in significant inhibition of tumor growth, 
whereas  similar  treatment  of  primary  tumors  derived 
from non-metastatic 67NR cells did not have an effect on 
tumor growth [23]. Furthermore, delivery of novel ureido 
sulfonamide [102] and glycosyl coumarin [103] inhibitors 
of CAIX into human and mouse models of orthotopic, 
CAIX-positive  breast  cancer  resulted  in  significant 
inhibition of primary tumor growth. An anti-tumor effect 
has also been demonstrated recently by inhibiting CAIX Oncotarget 2012; 3:  84 - 97 92 www.impactjournals.com/oncotarget
using an indanesulfonamide [84]. Interestingly, treatment 
of  HT-29  xenografts  with  this  high  affinity  inhibitor 
of CAIX resulted in reduced tumor growth, and further 
regression what observed when the inhibitor was used in 
combination with radiotherapy [84]. Collectively, these 
studies provide strong preclinical evidence for the use of 
CAIX inhibitors as targeted pharmacologic agents for the 
treatment of hypoxic, aggressive solid cancers.
In addition to their effects on the growth of hypoxic 
primary tumors, recent data suggest that sulfonamide and 
coumarin inhibitors of CAIX activity are efficacious in 
reducing metastatic burden in preclinical models of cancer. 
In two separate studies, treatment of experimental models 
of breast cancer metastasis with novel ureido sulfonamides 
has resulted in a significant decrease in lung metastases 
[23, 102]. Similar results have been achieved using novel 
glycosyl coumarins [23, 103], suggesting that this new 
generation of selective CAIX inhibitors have the capacity 
to work as targeted therapeutics for both the treatment 
of primary tumors and metastatic progression, at least in 
breast cancer.
CONCLUSION AND PERSPECTIVES
As solid malignancies progress, they often become 
hypoxic,  triggering  a  core,  HIF-1-mediated  signaling 
cascade that results in the activation of a plethora of genes 
vital for the adaptation of tumor cells to an increasingly 
stressful environment. As part of this response, tumor cells 
undergo a glycolyic switch that enables them to continue 
to grow in conditions of low oxygen. As a consequence 
of this altered metabolism, acidic metabolites are released 
into the extracellular environment, lowering the pHe and 
putting pressure on tumor cells to maintain their pHi. 
Therefore, cancer cells become increasingly reliant on a 
multi-component pH regulatory system for their continued 
survival and invasive behavior, and interference with one 
or more effectors of this system can prove detrimental to 
tumor growth.
CAIX  is  a  hypoxia-inducible  component  of  the 
tumoral pH regulatory system. Its upregulation results in 
dramatically enhanced hydrolysis of CO2 to HCO3
- and 
H+ at the extracellular surface of cancer cells, providing 
a chemical buffer that is actively transported into the cell 
to help maintain pHi and a source of H+ that contributes 
to the increasing acidosis of the extracellular space. As 
discussed here, it is now well-recognized that CAIX is 
highly overexpressed in several solid cancer types, in 
sharp contrast to the restricted expression of this protein 
in normal tissues, making it a clinically relevant target for 
novel cancer therapeutics.
Preclinical and clinical evaluation of novel CAIX-
selective therapies have, until recently, been slowed by 
the  lack  of  availability  of  appropriate  animal  models 
and the development of chemical compounds that 
selectively inhibit tumor associated, extracellular CAs 
without  “off-target”  inhibition  of  intracellular  CAs. 
However,  several  CAIX-targeted  therapeutic  agents, 
including  monoclonal  antibodies  and  small  molecule 
inhibitors, have been developed recently. Today, selective 
monoclonal  antibody  therapies  have  entered  clinical 
trials and several additional antibody-based modalities 
show  promise  in  experimental  models.  Importantly, 
inhibition  of  CAIX  with  sulfonamide-  or  coumarin-
based inhibitors is efficacious in reducing tumor growth 
and  inhibiting  metastasis  in  preclinical  tumor  models 
without the compromising effects of non-specific toxicity. 
These attributes suggest that such inhibitors are likely 
to  be  useful  clinically,  especially  if  administered  in 
combination  with  conventional  chemotherapy.  Indeed, 
the use of nontoxic targeted therapies in combination 
with conventional anticancer drugs or radiotherapy is the 
current clinical paradigm, and the inhibition of CAIX in 
this context may yield even better efficacy.
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